2.69

2.67% 0.07

After Hours: 2.74 0.05 +1.86%

Moleculin Biotech Inc (MBRX)

Overview News Price History Financials Discussions Forecast Stock Split

Moleculin Biotech Inc stock is traded at $2.69, with a volume of 19,871. It is up +2.67% in the last 24 hours and up +4.47% over the past month. Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Previous Close:

$2.62

Open:

$2.55

24h Volume:

19,871

Relative Volume:

0.50

Market Cap:

$7.96M

Revenue:

Net Income/Loss:

$-29.77M

P/E Ratio:

-2.6634

EPS:

-1.01

Net Cash Flow:

$-24.23M

1W Performance:

+0.75%

1M Performance:

+4.47%

6M Performance:

-45.44%

1Y Performance:

-67.45%

1-Day Range:

$2.54

$2.75

1-Week Range:

$2.50

$2.9332

52-Week Range:

$2.115

$15.75

Moleculin Biotech Inc Stock (MBRX) Company Profile

Name

Moleculin Biotech Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

713-300-5160

Address

5300 MEMORIAL DRIVE, HOUSTON, TX

Employee

Twitter

@moleculinbio

Next Earnings Date

2024-12-08

Latest SEC Filings

MBRX's Discussions on Twitter

Compare MBRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MBRX Moleculin Biotech Inc	2.69	7.96M	0	-29.77M	-24.23M	-1.01
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-18-22	Resumed	Oppenheimer	Outperform

Moleculin Biotech Inc Stock (MBRX) Latest News

Nov 21, 2024

Financial Comparison: Moleculin Biotech (NASDAQ:MBRX) & RedHill Biopharma (NASDAQ:RDHL) - Defense World

Nov 21, 2024

Nov 20, 2024

Moleculin Biotech Corporate Presentation Posted on Company WebsiteOn November 18, 2024, Moleculin Biotech, Inc. made public a corporate presentation on its official website. This presentation, identified as Exhibit 99.1 in the Current Report on Form - Defense World

Nov 20, 2024

Nov 19, 2024

What is Roth Capital’s Forecast for MBRX Q1 Earnings? - Defense World

Nov 19, 2024

Nov 18, 2024

Moleculin Biotech Unveils New Corporate Presentation - TipRanks

Nov 18, 2024

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML - PR Newswire

Nov 18, 2024

Nov 17, 2024

Moleculin Biotech Amends Clinical Trial Protocol for Phase 3 Trial - Defense World

Nov 17, 2024

Nov 15, 2024

Armistice Capital, LLC Expands Portfolio with Moleculin Biotech Inc Acquisition - GuruFocus.com

Nov 15, 2024

Moleculin (MBRX) Stock Jumps On Accelerated Clinical Trial News - Stocks Telegraph

Nov 15, 2024

Nov 14, 2024

Moleculin Biotech, Inc. Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia Pivotal Trial to H2 2025 - Marketscreener.com

Nov 14, 2024

Moleculin Biotech advances Annamycin AML trial protocol - Investing.com

Nov 14, 2024

Moleculin Biotech Accelerates Annamycin Phase 3 Trial - TipRanks

Nov 14, 2024

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025 - PR Newswire

Nov 14, 2024

Maxim Group Has Lowered Expectations for Moleculin Biotech (NASDAQ:MBRX) Stock Price - Defense World

Nov 14, 2024

Nov 12, 2024

Moleculin Biotech Reports Financial Highlights and Future Plans - Yahoo Finance

Nov 12, 2024

Moleculin gets IRB nod for Phase 3 AML trial - Investing.com India

Nov 12, 2024

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 12, 2024

Moleculin gets IRB nod for Phase 3 AML trial By Investing.com - Investing.com Nigeria

Nov 12, 2024

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) - PR Newswire

Nov 12, 2024

Nov 11, 2024

Earnings call: Moleculin Biotech optimistic on Annamycin's trial By Investing.com - Investing.com Australia

Nov 11, 2024

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire

Nov 11, 2024

Nov 08, 2024